Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

About half of CVD patients could be eligible for PCSK9 inhibitors

10 Jan 2018

About half of patients with cardiovascular disease (CVD) may be eligible for proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor therapy and results from a study of a large Canadian population-based cohort show such therapy may prevent CV events, though with significant costs. [Ko DT, et al, AHA 2017, abstract 778]

Among 62,729 adult patients with CVD, 61 percent, or 2.6 percent of the general population, were eligible for PCSK9 inhibitors based on eligibility criteria of the FOURIER trial (ie, fasting LDL-cholesterol 70 mg/dL or non–HDL-cholesterol ≥100 mg/dL while on an optimized lipid-lowering regimen).

“Applying the FOURIER hazard ratio to our study, we found a reduction in primary outcome [CV death, MI, unstable angina, stroke or coronary revascularization] of about 1.3 percent with PCSK9 inhibitors, which is similar to results of the FOURIER study,” said lead researcher Dr Dennis Ko of the Institute for Clinical Evaluative Sciences in Toronto, Ontario, Canada. 

“This was associated with a high cost per event,” he added, noting that the anticipated absolute clinical benefit in their trial may be smaller than reported in other PCSK9 inhibitor trials because of low overall event rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.